Zanicor
Zanicor Uses, Dosage, Side Effects, Food Interaction and all others data.
Zanicor is a dihydropyridine calcium-channel blocker which acts by inhibiting the influx of calcium ions through the slow channels of the vascular smooth muscle and myocardium during depolarization. Its main effect is vasodilatation because it has greater selectivity for vascular smooth muscle than cardiac smooth muscle.
Zanicor, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Zanicor is similar to other peripheral vasodilators. Zanicor inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Trade Name | Zanicor |
Generic | Lercanidipine |
Lercanidipine Other Names | Lercanidipine, Lercanidipino |
Type | |
Formula | C36H41N3O6 |
Weight | Average: 611.7272 Monoisotopic: 611.299536059 |
Groups | Approved, Investigational |
Therapeutic Class | Calcium-channel blockers |
Manufacturer | |
Available Country | Portugal, |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Zanicor is used for the treatment of mild to moderate essential hypertension.
Zanicor is also used to associated treatment for these conditions: High Blood Pressure (Hypertension), Mild Hypertension, Moderate Essential Hypertension
How Zanicor works
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Zanicor inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Dosage
Zanicor dosage
Use in elderly: The recommended dosage is 10 mg orally once a day at least 15 minutes before meals; the dose may be increased to 20 mg depending on the individual patient's response. It may take about 2 weeks before the maximal anti-hypertensive effect is apparent. Some individuals, not adequately controlled on a single antihypertensive agent, may benefit from the addition of Zanicor to therapy with a beta-adrenoceptor blocking drug (atenolol), a diuretic (hydrochlorothiazide) or an ACE inhibitor (ramipril).
Use in children: Since there is no clinical data in patients under the age of 18 years, use in children is not currently recommended.
Use in renal or hepatic dysfunction: Special care should be exercised in patients with mild to moderate renal or hepatic dysfunction. Dosage above 20 mg daily must be approached with caution. Zanicor is not recommended for use in patients with severe hepatic or renal dysfunction.
Should be taken on an empty stomach. Take at least 15 min before meals.
Side Effects
Treatment with Zanicor is generally well tolerated. The most common side effects are related to the vasodilatory properties of Zanicor such as flushing, peripheral edema, headache, dizziness and asthenia. Other side effects, which occurred in less than 1% of patients include fatigue; GI disturbances such as dyspepsia, nausea, vomiting, epigastric pain and diarrhea, polyurea, rash, somnolence and myalgia.
Precaution
Special care should be exercised when Zanicor is used in patients with sick sinus syndrome, left ventricular dysfunction and ischaemic heart disease.
Interaction
Plasma concentration reduced by inducers of CYP3A4 eg rifampicin, phenytoin, carbamazepine. Bioavailability also reduced by metoprolol and possibly propranolol. Plasma concentrations increased by inhibitors of CYP3A4 eg imidazole antifungals, erythromycin, ritonavir, fluoxetine. Alcohol may potentiate vasodilating effect.
Food Interaction
- Avoid alcohol. Alcohol may increase the vasodilatory effects of lercanidipine, which may lead to hypotension.
- Avoid grapefruit products. Grapefruit inhibits the metabolism of lercanidipine through CYP3A4, which causes increased serum levels of lercanidipine, and may increase the risk of hypotension.
- Exercise caution with St. John's Wort. Zanicor is metabolized by CYP3A4, and St. John's Wort is a CYP3A4 inducer.
- Take on an empty stomach. Taking lercanidipine after meals increases its bioavailability, therefore lercanidipine should be taken least 15 minutes before meals.
Pregnancy & Breastfeeding use
Pregnancy Category C. There is no clinical experience with lercanidipine in pregnancy, but other dihydropyridine compounds have been found to cause irreversible malformations in animals. Therefore, lercanidipine should not be administered during pregnancy or to women with child-bearing potential unless effective contraception is used.
Use in lactation: There is no clinical experience with lercanidipine in lactation. Distribution into milk may be expected, due to the high lipophilicity of lercanidipine. Therefore, lercanidipine should not be administered to lactating women.
Contraindication
Zanicor is contraindicated in patients with left ventricular outflow tract obstruction, untreated congestive cardiac failure, unstable angina pectoris, within 1 month of a myocardial infarction and known hypersensitivity to any dihydropyridine. Zanicor should not be taken with grapefruit juice.
Special Warning
Use in children: Since there is no clinical data in patients under the age of 18 years, use in children is not currently recommended.
Use in renal or hepatic dysfunction: Special care should be exercised in patients with mild to moderate renal or hepatic dysfunction. Dosage above 20 mg daily must be approached with caution. Zanicor is not recommended for use in patients with severe hepatic or renal dysfunction.
Acute Overdose
There have been no recorded cases of Zanicor overdosage. As with other dihydropyridines, overdosage might be expected to cause excessive peripheral vasodilatation with marked hypotension and reflex tachycardia.
Storage Condition
Should be stored in cool and dry place
Innovators Monograph
You find simplified version here Zanicor
Zanicor contains Lercanidipine see full prescribing information from innovator Zanicor Monograph, Zanicor MSDS, Zanicor FDA label